Filing Flows › Maxcyte (MXCT) › Q2 2026 › vs Q2 2025
Maxcyte (MXCT) Q2 2026 vs Q2 2025 (year over year)
Maxcyte's revenue fell $1.2M (-15%) from $8.5M in Q2 2025 to $7.3M in Q2 2026. The biggest changes: Product sales −$1.2M (-22%); Licenses −$338K (-12%); Assay and other service revenue +$273K (+88%).
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product sales | $4.1M | $5.3M | −$1.2M | -22% |
| Licenses | $2.6M | $2.9M | −$338K | -12% |
| Assay and other service revenue | $583K | $310K | $273K | +88% |
| Revenue | $7.3M | $8.5M | −$1.2M | -15% |
| Other income, net | $1.4M | $1.9M | −$512K | -27% |
| Net loss | $8.9M | $12.4M | −$3.5M | -28% |
| Costs & expenses | $17.5M | $22.7M | −$5.2M | -23% |
| Operating costs | $17.5M | $22.7M | −$5.2M | -23% |
| Cost of revenue | $1.7M | $1.5M | $156K | +10% |
| Research & development | $4.3M | $6.3M | −$2.0M | -32% |
| Sales & marketing | $3.4M | $5.8M | −$2.4M | -42% |
| General & admin | $7.3M | $8.1M | −$822K | -10% |
| Other operating costs | $953K | $1.1M | −$127K | -12% |
| Operating cash sources | $8.9M | $12.4M | −$3.5M | -28% |
| Depreciation & amortization | $978K | $1.1M | −$122K | -11% |
| Share-based compensation | $1.2M | $3.5M | −$2.4M | -67% |
| Working capital & other | $2.1M | −$2.1M | $4.2M | — |
| Cash used in operations | $4.7M | $9.9M | −$5.2M | -53% |
| Net loss absorbed | $8.9M | $12.4M | −$3.5M | -28% |
Questions
How much did Maxcyte's revenue grow year over year in Q2 2026?
Maxcyte's revenue fell $1.2M (-15%) from $8.5M in Q2 2025 to $7.3M in Q2 2026.
What drove Maxcyte's revenue change in Q2 2026?
Product sales −$1.2M (-22%); Licenses −$338K (-12%); Assay and other service revenue +$273K (+88%).